



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport

South Wales NP10 8QQ

WIPO

PCT

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

4 November 2003

BEST AVAILABLE COPY

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	24
Claim(s)	6
Abstract	1
Drawing(s)	3

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp & Co.
J.A. KEMP & CO.

Date 8 October 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

C H MERRYWEATHER
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

PROTEIN LATTICE

The present invention relates to protein lattices having a regular structure repeating in three dimensions. The protein lattices are based on symmetrical oligomer assemblies capable of self-assembly from the monomers of the oligomer assembly. Such protein lattices may have pores with dimensions of the order of nanometres to hundreds of nanometres. As such, the protein lattices are nanostructures which have many potential uses, but are particularly suitable as a matrix to support macromolecular entities for X-ray crystallography.

WO-00/68248 discloses regular protein structures based on symmetrical oligomer assemblies capable of self-assembly. In particular, WO-00/68248 discloses structures formed from protein protomers (referred to as a "fusion protein" in WO-00/68248) comprising at least two monomers (referred to as "oligomerization domains" in WO-00/68248) which are each monomers of a respective symmetrical oligomer assembly. Self-assembly of the monomers into the oligomer assembly causes assembly of the regular structures themselves. Several different types of structures are disclosed, including discrete structures and structures extending in one, two and three dimensions.

In WO-00/68248, the relative orientations of the monomers within the protomers are selected to provide the desired regular structure upon self-assembly. The monomers are fused together through a rigid linking group which is carefully selected to provide the requisite relative orientation of the monomers in the protomer. For example, in the laboratory production reported in WO-00/68248, the selection of the protomer was performed using a computer program to model monomers connected by a linking group in the form of a continuous, intervening alpha-helical segment over a range of incrementally increased lengths. Thus, the lattices suggested in WO-00/68248 having a regular structure repeating in three dimensions are formed from protomers comprising two monomers of respective dimeric or trimeric oligomer assemblies which are symmetrical about a single rotational axis. The relative orientation of the two monomers is selected to provide a specific angle of intersection between the rotational symmetry axis of the two oligomer assemblies. Thus, there is a single fusion between the two oligomer assemblies and the relative orientation of the oligomer assemblies is controlled by careful selection of the linking group providing the fusion.

WO-00/68248 only reports laboratory production of protein structures of a discrete cage and a filament extending in one dimension. It is expected that application of the teaching of WO-00/68248 to protein lattices repeating in three dimensions would encounter the following difficulties. Firstly, it is expected that there would be a difficulty
5 in design arising from the requirement to select the relative orientation of the monomers within the protomer appropriate for constructing a lattice. This would probably reduce the numbers of types of oligomer assembly available to form a protein lattice, and hence make it difficult to identify suitable proteins. Secondly, it is expected that practical difficulties would be encountered during assembly. The structures disclosed in WO-00/68248 rely on
10 the rigidity of the fusion between monomers in protomers which forms the single fusion between oligomer assemblies. WO-00/68248 teaches that the relative orientation of the monomers in the protomers controls the relative orientation of the oligomer assemblies in the resultant structure, so it is expected that flexing of the fusion away from the desired relative orientation would reduce the reliability of self-assembly. It is expected that such a
15 problem would become more acute as the size of the repeating unit increases, thereby providing a practical restriction on the reliable production of lattices with a relatively large pore sizes.

Accordingly, it would be desirable to provide protein lattices having a different type of structure in which these expected problems might be alleviated.

20 According to a first aspect of a present invention, there is provided a protein lattice having a regular structure with a repeating unit repeating in three dimensions, the repeating unit comprising protein protomers which each comprise at least two monomers fused together, the monomers each being monomers of a respective oligomer assembly into which the monomers are assembled for assembly of the protomers into the lattice, wherein
25 the repeating unit comprises protomers comprising at least a first monomer which is a monomer of a first oligomer assembly which has a quaternary structure which is symmetrical in three dimensions.

As a result of using at least a first oligomer assembly which is symmetrical in three dimensions, the structure of the repeating unit and hence the protein lattice is derived
30 from the symmetry of the oligomer assembly. In particular, it is not dependent on the relative orientation of the monomers within the protomer. Therefore, protein lattices in accordance with the present invention may be designed by selecting oligomers assemblies

wherein at least the first oligomer assembly has an appropriate three dimensional symmetry to build a lattice repeating in three dimensions. Protomers are then produced comprising monomers of the selective oligomer assemblies fused together. Subsequently, the protomers are allowed to self-assemble under suitable conditions. As described in more detail below, the chosen symmetries of the oligomer assemblies cause the protomers to self-assemble into the protein lattice.

To assist in understanding, reference is made to Fig. 1 which illustrates a particular example of a protein lattice 1 in accordance with the present invention, as described in more detail below. In particular, the protein lattice 1 has a regular structure with a repeating unit comprising a first oligomer assembly 3 which is symmetrical in three dimensions, which in this example is human heavy chain ferritin which has octahedral symmetry. Each of the monomers 5 of the first oligomer assembly 3 is fused to a further monomer 6 of a further oligomer assembly 4 which in this example is *E.coli* PurE has symmetry belonging to the dihedral D_4 point group 4. The further monomers 6 are assembled into the further oligomer assemblies 4 arranged with their rotational symmetry axes of order 4 aligned along the rotational symmetry axes of order 4 of the first oligomer assembly 3. Thus, the symmetry of the repeating unit and hence the protein lattice 1 is the same as the symmetry of the set of rotational symmetry axes of order 4 as will be described in more detail below the repeating unit and hence the lattice 1.

Accordingly, the present invention involves the use of a different class of oligomers assemblies from that used in WO-00/68248 and provides the benefit that one is not restricted by the selection of the relative orientation of the monomers within the protomer. Thus it is expected that the design of protein lattice will be assisted in that the relative orientation of the monomers within the protomer is a less critical constraint. Similarly, it is expected that more reliable assembly of the protein lattices will be possible, as described in more detail below.

According to other aspects of the present invention, there is provided an individual protomer or plural protomers capable of self-assembly to form such a protein lattice, as well as polynucleotides encoding such protomers, vectors and host cells capable of expressing such promoters and methods of making the protomers.

The present invention will now be described in more detail by way of non-limitative example with reference to the accompanying drawings in which:

Fig. 1 is a diagram schematically illustrating, for a first protein lattice, the design of a homologous protomer based on two oligomer assemblies and production of the lattice itself;

Fig. 2 is a diagram schematically illustrating, for a second protein lattice, the design of two heterologous protomers based on three oligomer assemblies and production of the lattice itself; and

Fig. 3 is a picture of an experimentally produced protein lattice of the type illustrated in Fig. 1.

Protein lattices in accordance with the present invention may be designed by selecting oligomer assemblies, at least a first of which is symmetrical in three dimension, which fused together produce a repeating unit which is capable of repeating in three dimensions. As the symmetry of the repeating unit, and hence the lattice as a whole, depends on the symmetry of the oligomer assemblies, this involves a selection of oligomer assemblies having a quaternary structure which provides appropriate symmetries. This is a straightforward task, because the symmetries of oligomer assemblies are generally available in the scientific literature on proteins, for example from The Protein Data Bank; H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov & P. E. Bourne; Nucleic Acids Research, 28 pp. 235-242 (2000) which is the single worldwide archive of structure data of biological macromolecules, also available through websites such as <http://www.rcsb.org>.

In some lattices, the repeating unit repeats in the same orientation across the lattice. In other lattices two or more adjacent repeating units together form a unit cell which repeats in the same orientation across the lattice, but with the repeating units within a unit cell arranged in different orientations.

Examples of oligomer assemblies which produce lattices with a repeating unit repeating in three dimension are given below.

Advantageously, the first oligomer assembly has a quaternary structure with a set of rotational symmetry axes extending in three dimensions. As a result, said repeating unit includes protomers with the first monomers of the protomers being assembled into said first oligomer assembly and, in respect of respective ones of said set of rotational symmetry axes, with further monomers of the protomers fused to respective first monomers being arranged symmetrically around said respective one of said set of

rotational symmetry axes.

The arrangement of the repeating unit, and hence the lattice as a whole, is therefore dependent on the symmetries of the first oligomer assembly. In particular, in the assembled first oligomer assembly, inevitably and by definition, there are groups of first monomers arranged symmetrically around each of the set of rotational symmetry axes of the first oligomer assembly. This is because the symmetry results from the identical monomers being so arranged around the rotational symmetry axes.

Since the further monomers are each fused to a respective first monomer, it follows that groups of the further monomers are also arranged symmetrically around each of the set of rotational symmetry axes. The further monomers are held in this symmetrical arrangement by being attached to first monomers in the first oligomer assembly. These groups of symmetrically arranged further monomers fused to the first oligomer assembly self-assemble with other monomers (which may be corresponding further monomers of another repeating unit, or may be monomers in a different part of the same unit cell) to form further oligomer assemblies, which are also arranged symmetrically around the set of rotational symmetry axes of the first oligomer assembly.

Thus, the arrangement of the repeating unit, and hence the lattice as a whole, is dependent on the symmetries of the first oligomer assembly, not on the relative orientation of the monomers within an individual protomer. In other words, the present invention provides the advantage that the three dimensional structure of the protein lattice may be based solely on the symmetries of the oligomer assemblies. This provides advantages in the design of the protein lattices. This is to say, the design of the repeating unit and hence the lattice as a whole may be based on the symmetries of the oligomer assemblies. This makes it easy to select appropriate oligomer assemblies for use in the protein lattice.

Desirably, the first oligomer assembly has a quaternary structure with a set of rotational symmetry axes extending in three dimensions, and, in said protomers, further monomers fused to said first monomers are monomers of respective further oligomer assemblies which have a rotational symmetry axis of the same order as a respective one of said set of rotational symmetry axes of said first oligomer assembly. As a result, said repeating unit includes protomers with the first monomers of the protomers being assembled into said first oligomer assembly and, in respect of respective ones of said set of rotational symmetry axes, with further monomers of the protomers fused to respective first

monomers being assembled into respective further oligomer assemblies with said rotational symmetry axis of said respective further oligomer assemblies being aligned with the respective rotational symmetry axis of said first oligomer assembly.

5 The arrangement of the repeating unit and hence the lattice as a whole are therefore dependent on the symmetries of the first and further oligomer assemblies. In particular, as described above, in the first oligomer assembly there are groups of first monomers arranged symmetrically around each of the set of rotational symmetries axes, which in turn result in groups of the further monomers fused to the first monomers also being arranged symmetrically around each of the set of rotational symmetry axes of the
10 first oligomer assembly. These groups of symmetrically arranged further monomers fused to the first oligomer assembly self-assemble with other monomers to form the further oligomer assembly. The further monomers may be further monomers of another repeating unit or may be monomers in a different part of the same repeating unit.

15 As a result of the further monomers fused to the first oligomer assembly being arranged symmetrically around a rotational symmetry axis of the first oligomer assembly, it follows that the further oligomer assembly is held with the group of fused further monomers also held symmetrically around that rotational symmetry axis of the first oligomer assembly. However, inevitably and by definition, the further monomers also assemble in the further oligomer assembly in a symmetrical arrangement around the
20 rotational symmetry axis of the further oligomer assembly. Thus, the result of the further oligomer assembly having a rotational symmetry axis of the same order as one of the set of rotational symmetry axes of the first oligomer assembly is that the first and further oligomer assemblies assemble with their symmetry axes aligned with one another. It follows from the symmetry of both oligomer assemblies that this is the most stable
25 arrangement. This results in an N-fold fusion between the first and further oligomer assemblies, where N is a plural number equal to the order of the respective rotational symmetry axis of the first oligomer assembly and the rotational symmetry axis of the further oligomer assembly. In each of the first and further oligomer assemblies, there are N monomers arranged around the rotational symmetry axis, each of the monomers being
30 fused within a respective protomer to a monomer of the other oligomer assembly.

Thus the set of rotational symmetry axes does not include all the rotational symmetry axes of the first oligomer assembly. Rather the set comprises the rotational

symmetry axes of the first oligomer assembly which are of the same order as rotational symmetry axes of the further oligomer assembly. For example in the example of Fig. 1, the set of rotational symmetry axes of the first oligomer assembly 3 are the rotational symmetry axes of order 4, rather than those of order 3 or 2, due to the further oligomer assembly 4 having rotational symmetry axes of order 4. Further examples are given below.

The particular choice of symmetries of the first and further oligomer assemblies results, on assembly of the protomers into the lattice, in the oligomer assemblies being built up with their rotational symmetry axes aligned. This means that the arrangement of the repeating unit, and hence the lattice as a whole, is controlled by the symmetries of the first and further oligomer assemblies, not on the relative orientation of the monomers within an individual protomer. In other words, the present invention provides the advantage that the three dimensional structure of the protein lattice may be based solely on the symmetries of the oligomer assemblies. This is advantageous in the design of the protein lattice. By basing the three dimensional structure of the repeating unit and hence lattice as a whole, on the symmetries of the oligomer assemblies, it is easier to select appropriate oligomer assemblies to form a lattice. During design, the relative orientation of the monomers within an individual protomer in its unassembled form becomes a much lower constraint than is present in, for example, WO-00/68248.

There are also expected to be advantages during self-assembly of the lattice. In particular, the formation of an N-fold fusion between two given oligomer assemblies results in the bond between the two oligomer assemblies being relatively rigid. This is expected to reduce relative motion of the oligomer assemblies during the assembly process. This is expected to assist in reliable formation of the lattice with the oligomer assemblies in the correct relative positions.

Although there are particular advantages in the use of a further oligomer assembly which has a rotational symmetry axis of the same order as the rotational symmetry axes of the first oligomer assembly, this is not essential. Alternatively, it would be possible for the further monomers arranged symmetrically around the rotational symmetry axes of the first oligomer assembly to be monomers of separate oligomer assemblies, for example of dimeric oligomer assemblies (being heterologous or homologous). In that case, the further oligomer assembly would effectively be replaced by a group of separate dimeric oligomer assemblies, equal in number to the order of the

rotational symmetry axis of the first oligomer assembly, with the separate dimeric oligomer assemblies held around the rotational symmetry axis of the first oligomer assembly in an arrangement which might or might not have the N-fold symmetry of the rotational symmetry axis of the first oligomer assembly.

5 The form and production of the protomers will now be described. Except that the present invention involves protomers in which a different choice of monomers from WO-00/68248 are fused together, the form and production of the protomers per se, as well as the polynucleotide encoding the protomers, may be as the same as disclosed in WO-00/68248 which is therefore incorporated herein by the reference.

10 The nature of the monomers themselves will now be described.

 The monomers are monomers of oligomer assemblies which are capable of self-assembly under suitable conditions to produce a protein lattice. The secondary and tertiary structure of the monomers is unimportant in itself providing they assemble into a quaternary structure with the required symmetry. However, it is advantageous if the
15 protein is easily expressed and folded in an heterologous expression system (for example using plasmid expression vector in *E.coli*).

 The monomers may be naturally occurring proteins, or may be modified by peptide elements being absent from, substituted in, or added to a naturally occurring protein provided that the modifications do not substantially affect the assembly of the
20 monomers into their respective oligomer assembly. Such modifications are in themselves known for a number of different purposes which may be applied to monomers of the present invention. In other words, the monomer may be a homologue and/or fragment and/or fusion protein of a naturally occurring protein.

 The monomer may be chemically modified, e.g. post-translationally modified.
25 For example, it may be glycosylated or comprise modified amino acid residues.

 The monomers are preferably fused genetically, although in principle other fusions are possible such as chemical fusions.

 Although the monomers may be fused directly together, preferably [claim 7] the monomers are fused by a linking group of peptide or non-peptide elements. In general,
30 linking two proteins by a linking group is known for other purposes and such linking groups may be applied to the present invention.

 Another factor in the selection of appropriate oligomer assemblies is the location

and orientation of (a) the termini of the first monomers when arranged in the first oligomer assembly in its natural form (i.e. not fused to a further oligomer assembly and (b) the termini of the further monomers when arranged in the further oligomer assembly in its natural form (i.e. not fused to the first oligomer assembly). Such information on the arrangement of the termini in the oligomer assembly in its natural form is generally available for oligomer assemblies, for example from The Protein Data Bank referred to above. Ideally, these termini should have the same separation and orientation, because they will be fused together in the assembled protein lattice to constitute the N-fold fusion arranged symmetrically around a rotational symmetry axis. That being said, it is not essential for the separation and orientation to be the same, because any difference may be accommodated by deformation of the monomers near the N-fold fusion and/or by use of a linking group. Therefore, as a general point, oligomer assemblies should be chosen in which the termini of both oligomer assemblies which are to be fused together in an N-fold fusion allows formation of the fusion without preventing assembly of the oligomer assemblies and hence the protein lattice.

Considering the deformation of the monomers near the N-fold fusion mentioned above, it is desirable to minimise such deformation which will tend to reduce the reliability of the assembly process. However, if a linking group is fused between the monomers, such deformation may be taken up, at least partially, by the linking group itself. This reduces the deformation of the monomers, thereby increasing the reliability of self-assembly because the linking group does not take part in the assembly process as regards to not being part of the naturally occurring protein. There is a particular advantage of the use of a linking group.

Furthermore, the linking group may be specifically designed to be [claim 8] oriented relative to the first and further monomers in the protomer in its normal form, prior to assembly, to reduce such differences in the position and/or orientation of the termini of the first and further monomers. Using position and orientation of the termini of the first and further monomers in the first and further oligomer assemblies in their natural form which is generally available for oligomer assemblies, as discussed above, it is possible to design an appropriate linking group using conventional modelling techniques.

Typically, the monomers are fused at their end termini. Alternatively, the monomers may be fused at an alternative location in the polypeptide chain so long as the

native fold and symmetry of the naturally occurring oligomer assembly remains the same. For example, one of the monomers may be inserted into a structurally tolerant portion of the other monomer, for example in a loop extending out of the oligomer assembly. Also, truncation of a monomer is feasible and may be estimated by structural examination.

5 Some examples of symmetries for the oligomer assemblies to produce a protein lattice are as follows.

In the examples, the first oligomer assembly which is symmetrical in three dimensions belongs to one of a tetrahedral point group, an octahedral point group or a dihedral point group.

10 In some classes of protein lattice, the protomers are homologous with respect to the monomers, ie there is a single type of protomer within the protein lattice. For example, Table 1 represents some simple homologous protomers capable of forming a protein lattice.

<u>Protomer</u>	<u>Class Name</u>	<u>M</u>	<u>N</u>
P ₃ P ₃	Platonic	12	3
P ₄ P ₄	Platonic	24	4
P ₄ P ₃	Platonic	24 (or 12)	3
p ₃ d ₃	Mixed	12	3
p ₃ d ₂	Mixed	12	2
20 p ₄ d ₄	Mixed	24	4
p ₄ d ₃	Mixed	24	3
p ₄ d ₂	Mixed	24	2
d ₃ d ₃ d ₂	Dihedral	6	3, 2
d ₄ d ₄ d ₂	Dihedral	8	4, 2
25 d ₆ d ₆ d ₂	Dihedral	12	6, 2

Table 1 - Homologous Protomers

In Table 1, each protomer is identified by letters which represent the respective monomers of the protomer. In particular the letters identify the point group to which the oligomer assembly of that monomer belongs. For each letter, the subscript number represents the order of the point group. The letter p represents a platonic point group, so p₃ represents a tetrahedral point group, and p₄ represents an octahedral point group. The letter d represents a dihedral point group.

30

In the final two columns of the table, there is given the number M of first monomers in the first oligomer assembly and the order(s) N of the set of rotational

symmetry axes of the first oligomer assembly. N is also the order of the rotational symmetry axis of the further oligomer assembly aligned with a respective rotational symmetry axis of the first oligomer assembly, and around which there is formed an N-fold fusion between the first and further oligomer assemblies.

5 The protomers have been divided into classes which have been named according to the nature of the monomers of the proteins for ease of reference.

In both the platonic and mixed classes, the first oligomer assembly belongs to a platonic point group, which is either a tetrahedral point group or an octahedral point group.

10 In the mixed class, the further monomer is a monomer of an oligomer assembly belonging to a dihedral point group. In each case, the order N of the dihedral point group, which is the order of the principal rotational symmetry axis of the dihedral point group, is equal to the order of one of the rotational symmetry axes of the first oligomer assembly. This may either be the principal rotational symmetry axis of the first oligomer assembly or one of the rotational symmetry axes of the first oligomer assembly of lower order. The rotational symmetry axes of the first oligomer assembly of order N therefore constitute the set of rotational symmetry axes of the first oligomer assembly. The symmetries of the first and further oligomer assemblies results in the formation of a unit cell in which the principal rotational symmetry axis of each further oligomer assembly belonging to a dihedral point group is aligned with one of set of rotational symmetry axes of order N of the platonic point group, with an N-fold fusion therebetween, in the manner described above.

15 The protein lattices of the mixed class are the easiest to visualise. In particular, the first oligomer assembly belonging to a platonic point group may be visualised as a node from which the set of rotational symmetry axes of order N extend outwardly. The dihedral point groups may be visualised as linear links with the principal rotational symmetry axis of the dihedral point group aligned with one of the set of rotational symmetry axes of order N of the first oligomer assembly. In this way, it is easy to visualise the formation of the lattice with pores in the spaces between the oligomer assemblies.

25 Fig. 1 illustrates a particular example of a protein lattice 1 belonging to the mixed class, in particular having a protomer 2 represented by $p_4 d_4$. The first oligomer assembly 3 is human ferritin heavy chain (HFH) which belongs to an octahedral point group. The further oligomer assembly is *E. coli* PurE which belongs to a dihedral D_4 point

group of order 4. The protomer comprises a first monomer 5 of the first oligomer assembly 3 and a further monomer 6 of the further oligomer assembly 4 fused together. On assembly, the protomers 2 form a lattice 1 in which the repeating unit (which is also a unit cell) may be taken as, for example, one of the first oligomer assemblies 3, together with and half of each of the adjacent second oligomer assemblies 4 formed by the further monomers 6 fused to the first monomers 5 of that first oligomer assembly 1. Clearly visible from Fig. 1 is the symmetry of the protein lattice 1 based on the symmetries of the first oligomer assembly 3 and the further oligomer assembly 4. In particular as the rotational symmetry axes of order 4 of the further oligomer assembly 4 are aligned with the set of rotational symmetry axes of order 4 of the first oligomer assembly 3 the symmetry of the lattice is the same as the symmetry of the set of rotational symmetry axes.

In the platonic class, the further oligomer assembly belongs to a platonic point group as well as the first oligomer assembly.

In the first two protein lattices where the protomers belong to platonic point groups of the same order, the first and further oligomer assemblies may be identical, in which case the first and further monomers are also identical, or may be different oligomer assemblies belonging to an identical point group. The set of rotational symmetry axes of order N around which is formed an N-fold fusion are the principal rotational symmetry axes of the two oligomer assemblies.

In the third protein lattice in the platonic class where the first and further oligomer assemblies belong respectively to tetrahedral and octahedral point groups (or vice versa), the rotational symmetry axes of order N around which the N-fold fusion occurs are the rotational symmetry axes of order 3 of the two oligomer assemblies. In this case, either one of the oligomer assemblies may be considered as the first oligomer assembly. If the oligomer assembly belonging to a tetrahedral point group is considered as the first oligomer assembly, then the set of rotational symmetry axes are the principal rotational symmetry axes. If the oligomer assembly belonging to an octahedral point group is considered as the first oligomer assembly, then the set of rotational symmetry axes are the set of rotational symmetry axes of order 3, because this is the order of the rotational symmetry axes of the further oligomer assembly belonging to the tetrahedral point group.

The platonic class may be visualised by considering each oligomer assembly as a node from which the set of rotational symmetry axes of order N extend outwardly and

joined to the rotational symmetry axes of an oligomer assembly of the opposite type.

Lastly, in the dihedral class, the protomers comprise three monomers all belonging to a dihedral point group. The central monomer may be considered as the first monomer of a first oligomer assembly belonging to a dihedral point group of order 3, 4 or 6. The monomers fused to each terminus of the first oligomer assembly may each be considered as the further monomers. One of the further monomers is a monomer of a further oligomer assembly belonging to a dihedral point group of the same order as the dihedral point group of the first oligomer assembly. Thus, as a result of the symmetries of the first oligomer assembly and this one of the further oligomer assembly, this results of the formation of a repeating unit in which the principal rotational symmetry axes of both oligomer assemblies (i.e. the rotational symmetry axis of the same order as the dihedral point group) are aligned. Therefore, in the protein lattice, these oligomer assemblies are arranged in columns along which the first and further oligomer assemblies are alternately arranged.

The other of the further monomers is a monomer of an oligomer assembly belonging to a dihedral point group of order 2 and so have a rotational symmetry axis of order 2 which is equal to the rotational symmetry axis of order 2 of the first oligomer assembly. Such rotational symmetry axes of the first oligomer assembly are equal in number to the order of the dihedral point group to which the first oligomer assembly belongs, and extend perpendicular to the principal rotational symmetry axis of the dihedral point group, being arranged symmetrically around that principal rotational symmetry axis. Therefore, the further oligomer assemblies belonging to a dihedral point group of order 2 are arranged in the assembled protein lattice with their principal rotational symmetry axes aligned to the just described rotational symmetry axes of order 2 of the first oligomer assembly. As these extend perpendicular to the principal rotational symmetry axes of the first oligomer assembly, the further oligomer assemblies belonging to a dihedral point group of order 2 may be considered as links between the columns of oligomer assemblies described above.

In other words, the set of rotational symmetry axes of the first oligomer assembly includes the principal rotational symmetry axis of order 3, 4 or 6, together with the rotational symmetry axes of order 2 perpendicular to the principal rotational symmetry axis.

In other classes of protein lattice, the protomers are heterologous with respect to the monomers i.e. there are two or more types of protomer in the protein lattice. To achieve assembly of any two types of protomer, the two types of protomer include different monomers of the same heterologous oligomer assembly. Thus when the protomers of the different types are allowed to assemble, the heterologous oligomer assemblies assemble, thereby linking the protomers of the two types. However, in contrast to homologous protomers, a single type of protomer cannot by itself assemble into the entire protein lattice. The individual monomers of the heterologous oligomer assembly cannot self-assemble into the entire heterologous oligomer assembly in the absence of the other, different monomers of that heterologous assembly. This provides advantages during manufacture of the protein lattices, because each type of protomer may be separately produced without assembly of an entire protein lattice which might otherwise disrupt the production of the protomer. This allows production in a two-stage process, which will be described in more detail below.

Preferably, the heterologous oligomer assembly belongs to a cyclic point group. In this case, the heterologous oligomer assembly may constitute a further oligomer assembly which is fused in the assembled lattice by an N-fold fusion to the first oligomer assembly.

In the simplest types of protein lattice, the heterologous protomers each further comprise a monomer of a homologous oligomer assembly, which may be the first oligomer assembly. The individual types of protomer may assemble into a respective, discrete component of the unit cell, as a result of the monomers of the homologous oligomer assembly self-assembling. This is an advantage of the heterologous protomers, because assembly of the lattice may be avoided until the components are brought together.

Otherwise assembly of the lattice might hinder the production of the protomers themselves.

For example, Table 2 represents some simple heterologous protomers capable of forming a protein lattice.

<u>Protomer</u>	<u>Components</u>	<u>Name</u>	<u>1st Protomer</u>		<u>2nd Protomer</u>	
			M	N	M	N
$P_3C_{3A} + P_3C_{3A}^*$	P_3/P_3	Platonic	12	3	12	3
$P_4C_{3A} + P_3C_{3A}^*$	P_4/P_4	Platonic	24	3	12	3
$P_4C_{3A} + P_3C_{3A}^*$	P_4/P_3	Platonic	24	3	12	3

5	$p_3c_{3A} + d_3c_{3A^*}$	P_3/D_3	Mixed	12	3		
	$p_3c_{2A} + d_3c_{2A^*}$	P_3/D_2	Mixed	12	2		
	$p_4c_{4A} + d_4c_{4A^*}$	P_4/D_4	Mixed	24	4		
	$p_4c_{3A} + d_3c_{3A^*}$	P_4/D_3	Mixed	24	3		
	$p_4c_{2A} + d_2c_{2A^*}$	P_4/D_2	Mixed	24	2		
10	$c_{3A}d_3d_2 + c_{3A^*}d_3d_2$	D_3/D_3	Dihedral	6	3, 2	6	3, 2
	$c_{4A}d_4d_2 + c_{4A^*}d_4d_2$	D_3/D_3	Dihedral	8	4, 2	8	4, 2
	$c_{6A}d_6d_2 + c_{6A^*}d_6d_2$	D_6/D_6	Dihedral	12	6, 2	12	6, 2
	$d_3d_3c_{2A} + d_3d_3c_{2A^*}$	D_3/D_3	Dihedral	6	3, 2	6	3, 2
	$d_4d_4c_{2A} + d_4d_4c_{2A^*}$	D_4/D_4	Dihedral	8	4, 2	8	4, 2
	$d_6d_6c_{2A} + d_6d_6c_{2A^*}$	D_6/D_6	Dihedral	12	6, 2	12	6, 2
	$c_{3A}d_3c_{2B} + c_{3A^*}d_3c_{2B^*}$	D_3/D_3	Dihedral	6	3, 2	6	3, 2
	$c_{4A}d_4c_{2B} + c_{4A^*}d_4c_{2B^*}$	D_4/D_4	Dihedral	8	4, 2	8	4, 2
	$c_{6A}d_6c_{2B} + c_{6A^*}d_6c_{2B^*}$	D_6/D_6	Dihedral	12	6, 2	12	6, 2

15. Table 2 - Heterologous Protomers

In Table 2, monomers of a single heterologous oligomer assembly belonging to a cyclic point group are used so that the protein lattice is formed from two types of protomer identified in the first column. Each of the protomers includes one of the monomers of the heterologous oligomer assembly.

20 In Table 2, the monomers of each protomer are identified by lower case letters in similar manner as in Table 1. The lower case letters p and d have the same meaning as in Table 1. In addition, lower case c represents a monomer of a heterologous oligomer assembly belonging to a cyclic point group. The subscript number again represents the order of the point group. The subscript capital letters A and A* are used to identify the two
25 different monomers of the same heterologous assembly.

In Table 2, the second column identifies the point groups to which the components resulting from the assembly of each type of protomer belongs. A similar notation is used as for the monomers of the protomer, except that capital letters are used to indicate that the point group of the component is being referred to. Thus capital letter P indicates that the component belongs to a platonic point group, so P_3 represents a
30 tetrahedral point group and P_4 represents an octahedral point group. Capital letter D indicates that the component belongs to a dihedral point group. In a similar manner to Table 1, the final columns give, in respect of each protomer where appropriate, the number M of monomers in the first oligomer assembly and the order(s) N of the set of rotational
35 symmetry axes of the first oligomer assembly which are aligned with the rotational

symmetry axis of a further oligomer assembly.

For ease of reference, the protein lattices are divided into classes on the basis of the symmetry of their components, in a similar manner to the division of the protein lattices formed from homologous protomers. In each case, the heterologous protomers may be derived from the protomers of the corresponding class of homologous protomer in Table 1.

For the mixed class and the platonic class, the two types of protomers both comprise:

- (a) a monomer of a homologous oligomer assembly which belongs to the same point group as a respective one of the monomers of the corresponding homologous protomer; and
- (b) a monomer which is a respective one of the two different monomers of the heterologous oligomer assembly which belongs to a cyclic point group.

The order of the cyclic point group to which the heterologous oligomer assembly belongs is the same as the order N of the N -fold fusion between the oligomer assemblies of the protein lattice formed from the corresponding homologous protomer, that is the order of the respective rotational symmetry axis of the first oligomer assembly.

Thus, in the assembled protein lattice, the repeating unit has fundamentally the same arrangement as the repeating unit of the corresponding homologous protomer, except as follows. Instead of the N -fold fusion between the two homologous oligomer assemblies of the homologous protomer, the link between the homologous oligomer assemblies is extended by the insertion of the heterologous oligomer assembly. Therefore, it will be seen that the repeating unit of the heterologous oligomer assembly effectively extends the length of the links of the repeating unit between the first oligomer assemblies which may be considered as nodes in the protein lattice. Thus, the size of the pores within the protein lattice is also increased relative to the use of the corresponding homologous protomers. Increasing the size of the pores in this manner represents a significant advantage of the use of heterologous protomers.

Fig. 2 illustrates a particular example of a protein lattice belonging to the mixed class, in particular having respective protomers 8 and 9 represented by p_3c_{3A} and d_3c_{3A*} , respectively. The first protomer 8 comprises a first monomer 10 of a first homologous oligomer assembly 11, namely is *E.coli* dps which belongs to a tetrahedral

point group. Fused to the first monomer 10 in the first protomer 8 is a further monomer 12 of a further heterologous oligomer assembly 13, namely bacteriophage T4 gp5 and gp27 which belongs to a cyclic point group of order 3. On assembly, the first protomer 8 forms a first component 14 by the first monomers 10 assembling together. The first component 14 has the same symmetry as the first oligomer assembly 11 of the first protomer 8.

5 The second protomer 9 comprises a monomer 15 which is the other monomer of the further oligomer 13 of the first protomer 8 which is heterologous to the further monomer 12 of the first protomer 8. The second protomer 9 also comprises a monomer 16 which is a monomer of a homologous oligomer assembly 17, namely human PTPS which 10 belongs to a dihedral D_3 point group of order 3. On assembly, the second protomer 9 forms a second component 18 by the homologous monomers 16 assembling together.

When the first and second components 14 and 18 are brought together, they assemble to form the protein lattice 7 by assembly of the heterologous oligomer assembly 13. It is clearly visible from Fig. 2 how the symmetry of the protein lattice 7 is based on 15 the symmetries of the homologous oligomer assemblies 11 and 17. In particular, the rotational symmetry axes of order 3 of both the heterologous oligomer assembly 13 and the homologous oligomer assembly 17 of the second protomer 9 are aligned with the set of rotational symmetry axes of order 3 of the first oligomer assembly 11 of the first protomer 8. It is further clear from Fig. 2 how the heterologous oligomer assemblies 13 effectively 20 extend the length of the links between the first oligomer assemblies 11. In the lattice 7, the repeating unit may be taken, for example, as one of the first components 14 and half of each of the adjacent second components 18. In this case, the unit cell is formed by a number of such repeating units combined together.

The protomers of the dihedral class of the heterologous comprise protomers 25 comprising three monomers which may be derived from a corresponding one of the dihedral class of homologous protomers. In particular, the two types of protomer comprise the corresponding homologous protomer with either one (or both) of the further monomers of the corresponding homologous protomers replaced by respective monomers of a heterologous oligomer assembly belonging to a cyclic point group of the same order as the 30 dihedral point group to which the oligomer assembly of the replaced monomer belongs.

The above examples of protein lattices are believed to represent the simplest form of protomers capable of forming a protein lattice and are preferred for that reason.

However, it will be appreciated that other protomers formed from monomers of oligomer assemblies having suitable symmetries will be capable of forming a protein lattice. For example, other homologous protomers having larger numbers of monomers than listed in Table 1 will be capable of forming a protein lattice. Similarly, other heterologous protomers will be capable of forming a protein lattice. These may include two types of protomer having larger numbers of monomers than in the examples of Table 2, or may include more than two types of protomer.

For each of the monomers, there is a large choice of oligomer assemblies having the required symmetry. The present invention is not limited to particular oligomer assemblies, because in principle any oligomer assembly having a quaternary structure with the requisite symmetry may be used. However, as examples Table 3 lists some possible choices of oligomer assembly for each of the point groups of Tables 1 and 2.

Point Group	Source	Name of Oligomer Assembly	PDB Code
P ₃ (T, 32)	<i>E.coli</i>	dps	1DPS
	<i>S.epidermis</i>	EpiD	1G63
P ₄ (O, 432)	Human	heavy chain ferritin	2FHA
	<i>E.coli</i>	Dihydrolipoamide succinyltransferase	1E2O
	<i>A.vinelandii</i>	Dihydrolipoamide acetyltransferase	1EAB
D ₂	Human	Mn superoxide dismutase	1AP5
	<i>P.falciparum</i>	lactate dehydrogenase	1CEQ
D ₃	Rat	6-pyruvoyl tetrahydropterin synthase	1B66
	<i>E.coli</i>	Amino acid aminotransferase	1IIL
D ₄	<i>E.coli</i>	PurE	1QCZ
	Sipunculid worm	Hemerythrin	2HMQ
D ₆	<i>S.typhimurium</i>	Glutamine Synthetase	1F1H
C _{2A} + C _{2A} *	Human	Casein kinase alpha and beta chains	1JWH
C _{3A} + C _{3A} *	Coliphage T4	gp5 + gp27	1K28
	HIV	N36 + C34	1AIK
	<i>Pseudomonas putida</i>	Napthalene 1,2-Dioxygenase	1NDO
C _{4A} + C _{4A} *	Erachiopod	Hemerythrin	N/A

Table 3 - Example oligomer assemblies

Thus the present invention provides a protein protomer or plural protein protomers capable of assembly into a protein lattice. The monomers of the protomer may be of any length but typically have a length of 5 to 1000 amino acids, preferably at least 20 amino acids and/or preferably at most 500 amino acids.

The invention also provides polynucleotides which encode the protein protomers of the invention. The polynucleotide will typically also comprise an additional sequence beyond the 5 and/or 3 ends of the coding sequence. The polynucleotide typically has a length of at least three times the length of the encoded protomer. The polynucleotide may be RNA or DNA, including genomic DNA, synthetic DNA or cDNA. The polynucleotide may be single or double stranded.

The polynucleotides may comprise synthetic or modified nucleotides, such as methylphosphonate and phosphorothioate backbones or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.

Such polynucleotides may be produced and used using standard techniques. For example, the comments made in WO-00/68248 about nucleic acids and their uses apply equally to the polynucleotides of the present invention.

The monomers are typically combined to form protomers by fusion of the respective genes at the genetic level (e.g. by removing the stop codon of the 5' gene and allowing an in-frame read through to the 3' gene). In this case the recombinant gene is expressed as a single polypeptide. The genes may, alternatively, be fused at a position other than the end terminus so long as the quaternary structure of the oligomer assembly properties remains substantially unaffected. In particular, one gene may be inserted within a structurally tolerant region of a second gene to produce an in-frame fusion.

Chemical fusion of the polypeptide chains may be used as an alternative to fusion at the genetic level. In this instance the polypeptides are fused post-translationally by means of the covalent linkage, but in particular through the use of intein chemistry.

The invention also provides expression vectors which comprise polynucleotides of the invention and which are capable of expressing a protein protomer of the invention. Such vectors may also comprise appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression.

Thus the coding sequence in the vector is operably linked to such elements so that they provide for expression of the coding sequence (typically in a cell). The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.

5 The vector may be for example, plasmid, virus or phage vector. Typically the vector has an origin of replication. The vector may comprise one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector.

10 Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include *S. cerevisiae* GAL4 and ADH promoters, *S. pombe nmt1* and *adh* promoter. Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used.

15 Mammalian promoters, such as β -actin promoters, may be used. Tissue-specific promoters are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters,
20 particularly the HPV upstream regulatory region (URR).

 Another method that can be used for the expression of the protein protomers is cell-free expression, for example bacterial, yeast or mammalian.

 The invention also includes cells that have been modified to express the protomers of the invention. Such cells include transient, or preferably stable higher
25 eukaryotic cell lines, such as mammalian cells or insect cells, using for example a baculovirus expression system, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells which may be modified by insertion of vectors encoding for a polypeptide according to the invention include mammalian
HEK293T, CHO, HeLa and COS cells. Preferably the cell line selected will be one which
30 is not only stable, but also allows for mature glycosylation of a polypeptide. Expression may be achieved in transformed oocytes.

The protein protomers, polynucleotides, vectors or cells of the invention may be present in a substantially isolated form. They may also be in a substantially purified form, in which case they will generally comprise at least 90%, e.g. at least 95%, 98% or 99%, of the proteins, polynucleotides, cells or dry mass of the preparation.

5 The protomers may be prepared using the vectors and host cells using standard techniques. For example, the comments made in WO-00/68248 regarding methods of preparing protomers (referred to as "fusion proteins" in WO-00/68248) apply equally to preparation of protomers according to the present invention.

10 Assembly of the protein lattice from the protomers may be performed simply by placing the protomers under suitable conditions for self-assembly of the monomers of the oligomer assemblies. Typically, this will be performed by placing the protomers in solution, preferably an aqueous solution. Typically, the suitable conditions will correspond to those in which the naturally occurring protein self-assembles in nature. Suitable conditions may be those specifically disclosed in WO-00/68248.

15 In the case of homologous protomers this results in direct assembly of the protein-lattice.

20 In the case of heterologous protomers, assembly is preferably performed in plural stages. In a first stage, each type of protomer is separately assembled into a respective discrete component. In a second stage, the discrete components are brought together and assembled into the protein lattice. Where plural heterologous protomers are used, there may be further stages intermediate the first and second stage in which the respective discrete components are brought together and assembled into larger, intermediate components.

25 A specific protein lattice of the type illustrated in Figure 1 has been prepared using the following method.

30 Human ferritin heavy chain (HFH) and the *E.coli* PurE gene were amplified by PCR from human cDNA and *E.coli* gDNA respectively. Primers for amplification of the ferritin gene were: 5'-CCT TAG TCG AAT TCA TGA CGA CCG CGT CCA CC-3' and 5'-GGG AAA TTA GCC CTC GAG TTA GCT TTC ATT ATC-3'. Primers for amplification of the PurE gene were: 5'-GTT TTA AGA CCC ATG GCT TCC CGC AAT AAT CCG-3' and 5'-CGC AAA CCT GGA TCC TGC CGC ACC TCG CGG-3'. The PurE gene was cloned into the pET-28b vector (Novagen) between the NcoI and BamHI

sites. The HFH gene was cloned into the resulting vector between the EcoRI and XhoI sites to create an in-frame fusion of the two genes under control of the T7lac promoter.

This vector was transformed into *E.coli* strain B834(pLysS) for expression.

Induction of expression was as follows: a 10ml overnight culture of the expression strain (in LB broth containing 30µg/ml Kanamycin) was diluted 1:100 into fresh LB broth containing 30µg/ml Kanamycin. Cells were grown with shaking at 37°C to a density corresponding to an OD₆₀₀ of 0.6 and were then induced to express the target protein by the addition of IPTG to a final concentration of 1mM. The culture was maintained at 37°C with shaking for a further 3 hours before the cells were harvested by centrifugation (5000g, 10min, 4°C). The cell pellet was resuspended in 20ml of buffer A (300mM NaCl, 1mM EDTA, 50mM HEPES, pH7.5). Cells were lysed by sonication and the insoluble fraction harvested by centrifugation (25,000g, 30 min, 4°C). This fraction was dissolved in 8M urea and centrifuged (25,000g, 30 min, 4°C) to remove insoluble particles. The urea solubilised material was concentrated to 16mg/ml and passed through a 0.22µm filter. A drop of this material (1µl) was then directly injected into a larger drop (5µl) of buffer A. Protein lattice particles were observed within one hour. Fig. 3 is a picture of one of the protein lattice particles having a diameter of approximately 0.6µm. The elemental composition of the protein lattice has been confirmed using µPIXE techniques.

Protein lattices in accordance with the present invention have numerous different uses. In general, such uses will take advantage of the regular repeating structure and the pores within the lattice. Lattices in accordance with the present invention may be designed to have pores with dimensions expected to be of the order of nanometres to hundreds of nanometres. Lattices may be designed with an appropriate pore size for a desired use.

As one example, the lattices are expected to be useful as a molecular sieve.

In addition, it is possible to attach macromolecular entities to the protein lattice using conventional techniques. The macromolecular entities may be any entities of an appropriate size, for example proteins, polypeptides or non-biological entities. As such, the protein lattices are expected to be useful as biological matrices for carrying macromolecular entities, for example for use in drug delivery, or for crystallizing macromolecular entities.

Attachment of the macromolecular entities to the protein lattice may be performed by "tagging" either or both of the protein protomers or the macromolecular entities of

interest. In this context, tagging is the covalent addition to either or both of the protein protomers or the target macromolecular entities, of a structure known as a tag which forms strong interactions with a target structure. The target structure may be a further tag attached to the other of the protein protomer or target macromolecular entity, or may be a part of the protein protomer or target macromolecular entity. In the case of the protein protomer, or a macromolecular entities which is a protein, this may be achieved by the expression of a genetically modified version of the protein to carry an additional sequence of peptide elements which constitute the tag, for example at one of its termini, or in a loop region. Alternative methods of adding a tag include covalent modification of a protein after it has been expressed, through techniques such as intein technology.

Thus to attach the macromolecular entity to the protein lattice, the protein protomers may include, at a predetermined position in the protomers, an affinity tag attached to the macromolecular entity of interest.

Alternatively, the macromolecular entity of interest may have at a predetermined position in the protomers, an affinity tag attached to a macromolecular entity.

When a component of the protein lattice is known to form strong interactions with a known peptide sequence, that peptide sequence may be used as a tag to be added to the target macromolecular entity. Where no such tight binding partner is known, suitable tags may be identified by means of screening. The types of screening possible are phage-display techniques, or redundant chemical library approaches to produce a large number of different short (for example 3-50 amino acid) peptides. The tightest binding peptide elements may be identified using standard techniques, for example amplification and sequencing in the case of phage-displayed libraries or by means of peptide sequencing in the case of redundant libraries.

To attach the macromolecular entity to the protein lattice using an affinity tag on the lattice or the macromolecular entity, the macromolecular entity may be allowed to diffuse into, and hence become attached to, a pre-formed protein lattice, for example by annealing of the bound macromolecular entity into their lowest energy configurations in the protein lattice may be performed using controlled cooling in a liquid nitrogen cryostream. Alternatively, the macromolecular entities may be mixed with the protomers during formation of the protein lattice to assemble with the lattice.

In particular, the protein lattices may be used to support an array of macromolecular

entities for X-ray crystallography of the macromolecular entities. In this case, the regular structure of the protein lattice allows the macromolecular entities to be held at a predetermined position relative to a repeating unit, so that they are held in a regular array and in a regular orientation. X-ray crystallography is important in biochemical research and rational drug design.

The protein lattice having an array of macromolecular entities supported thereof may be studied using standard x-ray crystallographic techniques. Use of the protein lattice as a support in x-ray crystallography is expected to provide numerous and significant advantages over current technology and protocol for X-ray crystallography, including the following:

(1) Significantly lower amounts of macromolecule will be required (probably of order micrograms rather than milligrams). This will allow determination of some previously intractable targets.

(2) Use of affinity tags will allow structure determination without the typical requirement for a number of purification steps.

(3) There will be no need to crystallize the macromolecular entity. This is a difficult and occasionally insurmountable step in traditional X-ray structure determination.

(4) There will be no need to obtain crystalline derivatives for each novel crystal structure to obtain the required phase information. Since the majority of scattering matter will be the known protein lattice in each case, determination of the structure may be automated and achieved rapidly by a computer user with little or no crystallographic expertise.

(5) The complexes of a protein with chemicals (substrates/drugs) and with other proteins can be examined without requiring entirely new crystallization conditions.

(6) The process is expected to be extremely rapid and universally applicable, which will provide enormous savings in time and costs.

CLAIMS

1. A protein lattice having a regular structure with a repeating unit repeating in three dimensions,

the repeating unit comprising protein protomers which each comprise at least two monomers fused together, the monomers each being monomers of a respective oligomer assembly into which the monomers are assembled for assembly of the protomers into the lattice,

wherein the repeating unit comprises protomers comprising at least a first monomer which is a monomer of a first oligomer assembly which is symmetrical in three dimensions.

2. A protein lattice according to claim 1, wherein the first oligomer assembly has a set of rotational symmetry axes extending in three dimensions,

whereby said repeating unit includes protomers with the first monomers of the protomers being assembled into said first oligomer assembly and, in respect of respective ones of said set of rotational symmetry axes, with further monomers of the protomers fused to respective first monomers being arranged symmetrically around said respective one of said set of rotational symmetry axes.

3. A protein lattice according to claim 2, wherein, in said protomers, said further monomers are monomers of a further oligomer assembly which has a rotational symmetry axis of the same order as the respective one of said set of rotational symmetry axes of said first oligomer assembly,

whereby said repeating unit includes said protomers with said further monomers being assembled into respective further oligomer assemblies with said rotational symmetry axis of each respective further oligomer assembly being aligned with said respective one of said set of rotational symmetry axes of said first oligomer assembly.

4. A protein lattice according to claim 1, wherein the first oligomer assembly has a set of rotational symmetry axes extending in three dimensions, and, in said protomers, further

monomers fused to said first monomers are monomers of respective further oligomer assemblies which have a rotational symmetry axis of the same order as a respective one of said set of rotational symmetry axes of said first oligomer assembly,

whereby said repeating unit includes protomers with the first monomers of the protomers being assembled into said first oligomer assembly and, in respect of respective ones of said set of rotational symmetry axes, with further monomers of the protomers fused to respective first monomers being assembled into respective further oligomer assemblies with said rotational symmetry axis of said respective further oligomer assemblies being aligned with the respective rotational symmetry axis of said first oligomer assembly.

5. A protein lattice according to any one of claims 2 to 4, wherein the orders of the rotational symmetry axes of said set of rotational symmetry axes are a respective one of 2, 3, 4 or 6.

6. A protein lattice according to any one of claims 2 to 5, wherein each of said monomers of said respective oligomer assemblies either is a naturally occurring protein or is based on a naturally occurring protein with peptide elements being absent from, substituted in, or added to the naturally occurring protein without substantially affecting assembly of monomers of said respective oligomer assembly.

7. A protein lattice according to claim 6, wherein, in said protomers, said monomers are fused via a linking group.

8. A protein lattice according to claim 7, wherein the linking group is oriented relative to the first and further monomers in the protomer in its normal form prior to assembly to reduce any difference in the assembled lattice in either or both of the position and orientation of (a) the termini of said first monomers in their arrangement in said first oligomer assembly in its natural form symmetrically around said respective one of said set of rotational symmetry axes of said first oligomer assembly, and (b) the termini of said further monomers in their arrangement in said further oligomer assembly in its natural form symmetrically around said rotational symmetry axis of said respective further oligomer assembly.

9. A protein lattice according to any one of claims 3 to 8, wherein the protomers are homologous with respect to the monomers.
10. A protein lattice according to claim 9, wherein said first oligomer assembly belongs to either a tetrahedral point group or an octahedral point group.
- 5 11. A protein lattice according to claim 10, wherein said further oligomer assembly belongs to a dihedral point group of the same order as the respective one of said set of rotational symmetry axes of said first oligomer assembly.
12. A protein lattice according to claim 10, wherein said further oligomer assembly belongs to either a tetrahedral point group or an octahedral point group.
- 10 13. A protein lattice according to claim 9, wherein said first oligomer assembly belongs to a dihedral point group of order 3, 4 or 6, and said protomers comprise at least two further monomers with a further monomer fused to each terminus of said first monomer of said first oligomer assembly.
- 15 14. A protein lattice according to claim 13, wherein one of said further monomers is a monomer of an oligomer assembly which belongs to a dihedral point group of the same order as the dihedral point group to which the first oligomer assembly belongs.
15. A protein lattice according to claim 14, wherein the other of said further monomers is a monomer of an oligomer assembly which belongs to a dihedral point group of order 2.
- 20 16. A protein lattice according to any one of claims 3 to 8, wherein the protomers are heterologous with respect to the monomers.
17. A protein lattice according to claim 16, wherein the unit cell includes protein protomers of two types, wherein the two types of protomer include different monomers of the same heterologous oligomer assembly.

18. A protein lattice according to claim 17, wherein at least a first type of protomer constitutes said protomers with the first monomers of the protomers being assembled into said first oligomer assembly and said further monomers of the protomers fused to respective first monomers are one of said different monomers of the same heterologous oligomer assembly, said heterologous oligomer assembly belonging to a cyclic point group.

19. A protein lattice according to claim 18, wherein said first oligomer assembly of the first type of protomer belongs to either a tetrahedral point group or an octahedral point group.

20. A protein lattice according to claim 19, wherein the second type of protomer comprises a monomer which is a monomer of an oligomer assembly belonging to a dihedral point group of the same order as said heterologous oligomer assembly.

21. A protein lattice according to claim 18, wherein the second type of protomer comprises a monomer which is a monomer of an oligomer assembly belonging to either a tetrahedral point group or an octahedral point group.

22. A protein lattice according to any one of the preceding claims having an array of macromolecular entities attached thereto.

23. A protein lattice according to claim 22, wherein the protomers have, at a predetermined position in the protomers, an affinity tag attached to a macromolecular entity.

24. A protein lattice according to claim 22 or 23, wherein the macromolecular entities have a peptide affinity tag attached to one of the protomers in the protein lattice.

25. Use of a protein lattice according to any one of claims 1 to 24 as a support for the array of macromolecular entities for x-ray crystallography of the macromolecular entities.

26. A method of performing x-ray crystallography comprising supporting an array of macromolecular entities on a protein lattice according to any one of claims 1 to 24 and performing x-ray crystallography on the lattice having the macromolecular entities supported thereon.

5 27. A protein protomer comprising at least two monomers fused together, the monomers each being monomers of a respective oligomer assembly into which the monomers are capable of self-assembly to assemble at least part of a repeating unit of a protein lattice having a regular structure repeating in three dimensions, wherein, in said protomer, at least a first monomer is a monomer of a first oligomer assembly which is
10 symmetrical in three dimensions.

28. A protein promoter according to claim 27, wherein the first oligomer assembly has a set of rotational symmetry axes extending in three dimensions, and, in said protomers, further monomers fused to the first monomers are monomers of respective further oligomer assemblies which have a rotational symmetry axis of the same order as a respective one of
15 said set of the rotational symmetry axes of said first oligomer assembly,

whereby said repeating unit includes protomers with the first monomers of the protomers being assembled into said first oligomer assembly and, in respect of respective ones of said set of rotational symmetry axes, with further monomers of the protomers fused to respective first monomers being assembled into respective further oligomer assemblies
20 with said rotational symmetry axis of said respective further oligomer assemblies being aligned with the respective rotational symmetry axis of said first oligomer assembly.

29. Plural different protein protomers according to claim 27 or 28, wherein the monomers of the plural different protomers are capable of self-assembly with each other to form the entire protein lattice.

25 30. A polynucleotide encoding a protein protomer according to claim 27 or 28 or one of the respective protein protomers of said plural different proteins according to claim 29.

31. A vector capable of expressing a protomer according to claim 27 or 28 or one of the

respective protein protomers of said plural different protein protomers according to claim 29.

32. A host cell comprising a vector according to claim 31.

5 33. A method of making a protein protomer according to claim 27 or 28 or one of the respective protein protomers of said plural different protein protomers according to claim 29, comprising expressing a polynucleotide sequence which encodes the protomer in a host cell and, optionally, purifying the expressed protomer.

34. A method of making a protein lattice according to any one of claims 1 to 24.


Abstract

Protein Lattice

Protein lattices 1 having a regular structure with a repeating unit repeating in three dimensions may have many uses, for example to support an array of macromolecular entities for x-ray crystallography. The repeating unit comprises protein protomers 2 which each comprise at least two monomers 5, 6 fused together. The monomers 5, 6 are each monomers of a respective oligomer assembly 3, 4 into which the monomers are assembled for assembly of the protomers into the lattice. The first oligomer assembly 3 has a set of rotational symmetry axes extending in three dimensions. In said protomers 2, further monomers 6 fused to said first monomers 5 are monomers of respective further oligomer assemblies 4 which have a rotational symmetry axis of the same order as a respective one of said set of rotational symmetry axes of said first oligomer assembly 3. Thus, the repeating unit includes protomers 2 with the first monomers 5 of the protomers 2 being assembled into said first oligomer assembly 3 and, in respect of respective ones of said set of rotational symmetry axes, with further monomers 6 of the protomers 2 fused to respective first monomers 3 being assembled into respective further oligomer assemblies 4. As a result of the symmetry of the oligomer assemblies 3, 4 said rotational symmetry axis of said respective further oligomer assemblies 4 is aligned with the respective rotational symmetry axis of said first oligomer assembly 3. Thus, an N-fold fusion between the oligomer assemblies 3, 4 is produced and the rotational symmetry axes of the oligomer assemblies 3, 4 define the symmetry of the lattice.

FIG.1

Protein Lattice
 p_4d_4




Self-Assembly

Protomer
 p_4d_4



Gene Fusion

Assemblies
O and D_4



Homologous
O
Human Heavy Chain
Ferritin



Homologous
 D_4
E.coli PurE

2

FIG.2

Protein Lattice
P₃/D₃

Components
P₃ and D₃

Protomers
P₃C₃A and d₃C₃A*

Assemblies
T, C₃ and D₃

Homologous
T
E.coli dps

Heterologous
C₃
Bacteriophage T4 gp5 and gp27

Homologous
D₃
Human PTPS






Fig. 3





1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

N.85849.GHM

- 8 OCT 2002

2. Patent application number

(The Patent Office will fill in this part)

0223323.7

090CT02 E754144-3 D00192
P01/7700 0.00-0223323.7

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ISIS INNOVATION LIMITED
Ewert House, Ewert Place
Summertown
Oxford OX2 7SG

Patents ADP number (if you know it)

840898/001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

PROTEIN LATTICE

5. Name of your agent (if you have one)

J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.